Wegovy HD Rollout: Novo Nordisk Introduces 7.2 mg Dose in US Market
Bengaluru: Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States.
The 7.2-milligram dose, branded as Wegovy HD, gained approval under the FDA Commissioner's National Priority Review Voucher program last month.
Before the approval, the highest authorized dose of the injectable Wegovy for weight loss was 2.4 mg.
The company said the higher-dose Wegovy will be available through U.S. pharmacies, NovoCare Pharmacy and select telehealth providers.
Cash-paying adults prescribed Wegovy HD can expect to pay $399 per month, while commercially insured patients may pay as little as $25 per month using the Wegovy savings offer, Novo said. Last month, Novo said it plans to launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering steep discounts to regain ground ceded to Eli Lilly in the obesity-drug market.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.